Postmenopausal Breast Cancer, Aromatase Inhibitors, and Bone Health: What the Surgeon Should Know.

摘要: Breast cancer, as the most common malignancy in women, remains a major public health issue despite countless advances across decades. Endocrine therapy is cornerstone of treatment hormone-sensitive subtype breast cancer. The use aromatase inhibitors (AIs) postmenopausal women has extended survival beyond that Tamoxifen, but harbors subset side effects, notably accelerated bone loss. This, however, does not occur all undergoing treatment. It vital to identify susceptible patients early, limit such events, employ early thereof, or alter drug therapy. International trials on AIs, predominantly performed North American and European females, provide little information what expect developing countries. Here, surgeons often prescribe manage endocrine prescribing surgeon should be aware adverse effect able attend effects. This review highlights clinical biochemical factors associated with decrease mineral density an, yet, unidentified subgroup women. In era personalized medical care, appropriate management by based these becomes increasingly important.